Stoke Therapeutics Second Quarter 2025 Business Update Webcast for Investors & Analysts August 12, 2025 © COPYRIGHT 2025 | STOKE THERAPEUTICS | 1 Agenda CEO Opening Remarks Ian F. Smith, Interim Chief Executive Officer & Director Phase 3 Design and Progress Barry Ticho, M.D., Ph.D., Chief Medical Officer Long-Term 36-Month OLE Data Kimberly Parkerson, M.D., Ph.D., SVP, Head of Neurology Clinical Development Pipeline Update: ADOA Preclinical Data and Development Plan Barry Ticho, M.D., Ph.D., Chief Medical O ...